drugset / Trial / NCT05543330
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2026-09-15
- Completion
- 2026-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 30 mg/m2 | Other |
| Comparator | Cisplatin | Other / unclassified | 50 mg/m2 | Other |
| Subject | M701 | Monoclonal antibody | — | Other |